Sun Pharma

Sun Pharmaceutical Industries has initiated a recall of an antifungal shampoo from the U.S. market after concerns flagged by the U.S. Food and Drug Administration. The action underscores the heightened regulatory scrutiny facing global drugmakers operating in tightly controlled overseas markets. While the recall does not alter Sun Pharma’s core business fundamentals, it highlights the operational and compliance challenges inherent in complex pharmaceutical supply chains.

Sun Pharmaceutical Industries, India’s largest drugmaker, is facing potential headwinds from proposed tariff measures in the United States. The company, which derives a significant portion of its revenue from the U.S. generics market, may see margins pressured if additional duties are imposed on pharmaceutical imports. While the full scope of the tariffs is yet to be finalized, analysts caution that such measures could disrupt supply chains, raise compliance costs, and reshape competitive dynamics in the world’s largest drug market.